Busarin Arunsak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9995485/publications.pdf

Version: 2024-02-01

23 papers	272 citations	1040056 9 h-index	996975 15 g-index
23 all docs	23 docs citations	23 times ranked	139 citing authors

#	Article	IF	Citations
1	Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats. Nutritional Neuroscience, 2022, 25, 1115-1127.	3.1	14
2	Inhibition of myeloid differentiation factor 2 attenuates cardiometabolic impairments via reducing cardiac mitochondrial dysfunction, inflammation, apoptosis and ferroptosis in prediabetic rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166301.	3.8	9
3	L6H21 protects against cognitive impairment and brain pathologies via tollâ€like receptor 4â€“myeloid differentiation factor 2 signalling in prediabetic rats. British Journal of Pharmacology, 2022, 179, 1220-1236.	5.4	6
4	Therapeutic potentials of cell death inhibitors in rats with cardiac ischaemia/reperfusion injury. Journal of Cellular and Molecular Medicine, 2022, 26, 2462-2476.	3.6	15
5	Effectiveness of high cardiorespiratory fitness in cardiometabolic protection in prediabetic rats. Molecular Medicine, 2022, 28, 31.	4.4	6
6	The roles of <scp>HMGB1</scp>â€produced <scp>DNA</scp> gaps in <scp>DNA</scp> protection and aging biomarker reversal. FASEB BioAdvances, 2022, 4, 408-434.	2.4	12
7	Hyperbaric oxygen therapy improves age induced bone dyshomeostasis in non-obese and obese conditions. Life Sciences, 2022, 295, 120406.	4.3	6
8	Acetylcholine receptor agonists provide cardioprotection in doxorubicin-induced cardiotoxicity via modulating muscarinic M2 and Î±7 nicotinic receptor expression. Translational Research, 2022, 243, 33-51.	5.0	8
9	Modulation of mitochondrial dynamics rescues cognitive function in rats with â€˜doxorubicinâ€induced chemobrainâ€™ via mitigation of mitochondrial dysfunction and neuroinflammation. FEBS Journal, 2022, 289, 6435-6455.	4.7	8
10	Mild Cognitive impairment Occurs in Rats During the Early Remodeling Phase of Myocardial Infarction. Neuroscience, 2022, 493, 31-40.	2.3	5
11	Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats. Cellular and Molecular Life Sciences, 2022, 79, 300.	5.4	7
12	Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy. Neurotherapeutics, 2021, 18, 2107-2125.	4.4	30
13	Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics. Biochemical Pharmacology, 2021, 192, 114743.	4.4	46
14	Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis. Pharmacological Research, 2021, 173, 105882.	7.1	27
15	Cell death inhibitors protect against brain damage caused by cardiac ischemia/reperfusion injury. Cell Death Discovery, 2021, 7, 312.	4.7	31
16	Proprotein convertase subtilisin/kexin type 9 inhibitor and atorvastatin exert greater efficacy than estrogen on attenuating brain pathology and learning deficit in obesity with estrogenâ€deprived condition. Alzheimer's and Dementia, 2021, 17, e050808.	0.8	0
17	Blocking myeloid differentiation factor 2 improves cognitive function via reducing microglia activation, neuroinflammation, brain mitochondrial dysfunction and dendritic spine loss in obese insulinâ€resistant rats. Alzheimer's and Dementia, 2021, 17, e050382.	0.8	1
18	Myeloid differentiation factor 2 inhibitor, 2iâ€10, alleviates dendritic spine loss in rats with cardiac ischemiaâ€reperfusion injury via decreasing brain inflammation. Alzheimer's and Dementia, 2021, 17, e051260.	0.8	0

#	Article	IF	Citations
19	PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats. European Journal of Pharmacology, 2020, 883, 173347.	3.5	5
20	A proprotein convertase subtilisin/kexin type 9 inhibitor provides comparable efficacy with lower detriment than statins on mitochondria of oxidative muscle of obese estrogen-deprived rats. Menopause, 2020, 27, 1155-1166.	2.0	5
21	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Archives of Biochemistry and Biophysics, 2020, 689, 108470.	3.0	9
22	PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca²⁺ regulation. Journal of Cellular and Molecular Medicine, 2020, 24, 9189-9203.	3.6	9
23	The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats. Toxicology and Applied Pharmacology, 2019, 382, 114741.	2.8	13